ArticleBiochemical and biophysical research communications2025
Taming Bacterial Toxins into an Anticancer Platform.
Article in Biochemical and biophysical research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A hallmark of cancer is uncontrolled cell growth, which leads to hypoxia. Hypoxia causes significantly increased expression of a carbohydrate antigen Sialyl Lewis X (SLeX). The expression of SLeX correlates with recurrence, poor prognosis, and a low survival rate in a broad spectrum of cancers. Treatment targeting SLeX inhibits cancer cell migration and stimulates cell death, bringing a new chapter to cancer therapy. Our previous study shows that SSL11 (staphylococcal superantigen-like protein 11) mediates cell motility arrest by inducing adhesion via binding to SLeX. The properties of binding glycan SLeX and inhibiting the cell motility of SSL11 make it an appealing delivery platform against cancers that overexpress SLeX. Pseudomonas exotoxin A (PE) is an ADP-ribosylating AB toxin used to construct immunotoxins by replacing the receptor-binding domain with antibodies. A truncated and mutated form of PE (PE24
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.